The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
Protein platforms revenues grew 21 percent, while biotechnology revenues were up 18 percent, and diagnostic revenues increased 2 percent.
Exosome markets a urine-based test called ExoDx Prostate (IntelliScore) to help determine whether patients with ambiguous PSA tests needs a prostate biopsy.
Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.
A brief recap of Genetics/Genomics news the week of Jun 15, 2018: Epistem, Exosome Diagnostics, Luminex, Bluebee, Abomics, and OpGen
The company has highlighted the study as evidence that its test would outperform Roche's FDA-approved liquid biopsy assay if implemented in the clinic.
The company will design and validate a test using its Exolution isolation kit, which can stratify and monitor patients in Intezyne's clinical trials of IT-139.
Based on technology developed at Mass General, the platform will allow the company and its customers to add protein detection to nucleic acid analysis.
The coverage decision is based on the results of an evidence development study the companies launched last year.
A research collaboration involving several universities has yielded a technique that they said isolates exosomes from biological samples more effectively than incumbent methods.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.